JDM Financial Group LLC Sells 31,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

JDM Financial Group LLC trimmed its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 90.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,500 shares of the company’s stock after selling 31,500 shares during the period. JDM Financial Group LLC’s holdings in Perspective Therapeutics were worth $47,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in CATX. WealthPlan Investment Management LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $4,530,000. Hills Bank & Trust Co bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $13,722,000. Janus Henderson Group PLC boosted its stake in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Nicholson Wealth Management Group LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $21,390,000. Finally, FMR LLC boosted its stake in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Wall Street Analysts Forecast Growth

CATX has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush reissued an “outperform” rating and set a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer cut their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Finally, UBS Group initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 8,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer now directly owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares in the company, valued at approximately $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Stock Up 0.3 %

CATX opened at $3.77 on Tuesday. Perspective Therapeutics, Inc. has a twelve month low of $2.28 and a twelve month high of $19.05. The company has a 50-day simple moving average of $9.56 and a 200 day simple moving average of $11.79.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.